Megan Gates
About Megan Gates
Megan Gates: Vice President of Human Resources and Talent Acquisition
Megan Gates serves as the Vice President of Human Resources and Talent Acquisition. She plays a pivotal role in shaping the HR strategies and talent acquisition efforts for her organization. Her responsibilities include overseeing the recruitment process, developing HR policies, and ensuring the alignment of HR initiatives with the company’s overall strategic goals.
Megan Gates' Career at Bristol Myers Squibb
Before her current role, Megan Gates worked at Bristol Myers Squibb as the Director of Talent Acquisition. During her tenure, she was instrumental in developing strategic planning and executing the global Research & Early Development organization’s recruitment plan. Her efforts were especially significant following the acquisition of Celgene, where she ensured a seamless integration process and effective talent acquisition strategies to support the expanded organization.
Megan Gates' Expertise in HR and Talent Acquisition
With over 20 years of combined experience in Human Resources and Talent Acquisition, Megan Gates has a profound understanding of the life sciences industry. Her expertise includes strategic HR planning, talent management, recruitment strategies, and organizational development. Her extensive experience ensures that she can effectively lead HR and talent acquisition initiatives that support the growth and development of her organization.
Strategic Recruitment Planning by Megan Gates
Megan Gates has demonstrated a strong capability in strategic recruitment planning. At Bristol Myers Squibb, she was responsible for the strategic planning and execution of the global Research & Early Development organization’s recruitment plan. Her work involved collaborating with various stakeholders to identify recruitment needs, designing effective recruitment strategies, and ensuring the alignment of these strategies with the organization's objectives, particularly during significant corporate changes like the acquisition of Celgene.